Strategic Partners aktie (STRAP) | Pressmeddelande - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Investeringsmöjlighet: Bli delägare i global ledare inom AI-baserad videoanalys på säkerhetsmarknaden (annons)

Pressmeddelanden från Strategic Partners

 Bevaka pressreleaser
Kurs från TradingView
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

Business update - opdatering på identitetsændring:

Business update - opdatering på identitetsændring:

GlobeNewswire • 18 Sep 15:26

Periodemeddelelse Første Kvartal 2024

Periodemeddelelse Første Kvartal 2024

GlobeNewswire • 14 May 10:55

Referat Fra Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00

Referat Fra Ordinær Generalforsamling Den 18. April 2024 Kl.

GlobeNewswire • 18 Apr 15:39

Indkaldelse Til Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00

Indkaldelse Til Ordinær Generalforsamling Den 18. April 2024 Kl.

GlobeNewswire • 27 Mar 14:20

Årsregnskab 2023 – Et begivenhedsrigt år for selskabet

Årsregnskab 2023 – Et begivenhedsrigt år for selskabet

GlobeNewswire • 27 Mar 13:50

Foreløbige tal for 2023 og finansielle forventninger til 2024

Foreløbige tal for 2023 og finansielle forventninger til 2024

GlobeNewswire • 25 Mar 16:04

Change in management

Change in management

GlobeNewswire • 30 May 2023 19:41

Major shareholder announcement

Major shareholder announcement

GlobeNewswire • 19 May 2023 09:21

Major shareholder announcement

Major shareholder announcement

GlobeNewswire • 17 May 2023 18:51

Resolutions passed at the Annual General Meeting

Resolutions passed at the Annual General Meeting

GlobeNewswire • 17 May 2023 15:29

Changes to the Board of Directors

Changes to the Board of Directors

GlobeNewswire • 17 May 2023 12:44

Major shareholder announcement

Major shareholder announcement

GlobeNewswire • 12 May 2023 18:02

Major shareholder announcement

Major shareholder announcement

GlobeNewswire • 09 May 2023 10:45

Major shareholder announcement

Major shareholder announcement

GlobeNewswire • 09 May 2023 10:35

Notice to convene Annual General Meeting

Notice to convene Annual General Meeting

GlobeNewswire • 25 Apr 2023 22:27

Orphazyme Announces Publication of 2022 Financial Results and Annual Report

Orphazyme Announces Publication of 2022 Financial Results and Annual Report

GlobeNewswire • 25 Apr 2023 22:20

Change to Financial Calendar for 2023 and update regarding class action lawsuit in United States

Change to Financial Calendar for 2023 and update regarding class action lawsuit in United States

GlobeNewswire • 17 Apr 2023 08:52

Orphazyme reports financial results in Interim Report First Half 2022

Orphazyme reports financial results in Interim Report First Half 2022

GlobeNewswire • 26 Sep 2022 17:25

Adjusted financial outlook for 2022

Adjusted financial outlook for 2022

GlobeNewswire • 25 Sep 2022 22:09

Updated financial calendar for 2022

Updated financial calendar for 2022

GlobeNewswire • 19 Sep 2022 19:41

Resolutions passed at the Annual General Meeting

Resolutions passed at the Annual General Meeting

GlobeNewswire • 29 Jun 2022 16:27

Updated notice to holders of ADSs regarding termination of Deposit Agreement

Updated notice to holders of ADSs regarding termination of Deposit Agreement

GlobeNewswire • 20 Jun 2022 19:50

Correction: Orphazyme Announces Publication of 2021 Financial Results and Annual Report

Correction: Orphazyme Announces Publication of 2021 Financial Results and Annual Report

GlobeNewswire • 08 Jun 2022 23:07

Notice to convene Annual General Meeting

Notice to convene Annual General Meeting

GlobeNewswire • 07 Jun 2022 23:47

Orphazyme Announces Publication of 2021 Financial Results and Annual Report

Orphazyme Announces Publication of 2021 Financial Results and Annual Report

GlobeNewswire • 07 Jun 2022 23:34

Orphazyme completes sale of substantially all of its assets and business activities to KemPharm

Orphazyme completes sale of substantially all of its assets and business activities to KemPharm

GlobeNewswire • 31 May 2022 18:57

Restructuring proposal adopted by creditors

Restructuring proposal adopted by creditors

GlobeNewswire • 30 May 2022 14:55

Changes to the Board of Directors

Changes to the Board of Directors

GlobeNewswire • 23 May 2022 08:52

Restructuring Proposal

Restructuring Proposal

GlobeNewswire • 18 May 2022 16:35

Updated Financial Calendar for 2022

Updated Financial Calendar for 2022

GlobeNewswire • 16 May 2022 14:50

Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.

Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.

GlobeNewswire • 15 May 2022 23:00

Orphazyme announces update on in-court restructuring proceedings

Orphazyme announces update on in-court restructuring proceedings

GlobeNewswire • 29 Apr 2022 08:46

Updated Financial Calendar for 2022

Updated Financial Calendar for 2022

GlobeNewswire • 28 Apr 2022 16:13

Statutory restructuring plan adopted by creditors

Statutory restructuring plan adopted by creditors

GlobeNewswire • 07 Apr 2022 12:08

Updated Financial Calendar for 2022

Updated Financial Calendar for 2022

GlobeNewswire • 06 Apr 2022 14:48

Notice received from the Depositary to holders of ADSs regarding termination of Deposit Agreement

Notice received from the Depositary to holders of ADSs regarding termination of Deposit Agreement

GlobeNewswire • 06 Apr 2022 10:00

Correction: Proposal for a statutory restructuring plan

Correction: Proposal for a statutory restructuring plan

GlobeNewswire • 04 Apr 2022 19:44

Voluntary delisting of ADSs has become effective

Voluntary delisting of ADSs has become effective

GlobeNewswire • 31 Mar 2022 23:37

Proposal for a statutory restructuring plan

Proposal for a statutory restructuring plan

GlobeNewswire • 31 Mar 2022 18:00

Updated Financial Calendar for 2022

Updated Financial Calendar for 2022

GlobeNewswire • 29 Mar 2022 13:15

Orphazyme announces withdrawal of European Marketing Authorisation Application for arimoclomol for the treatment of Niemann-Pick disease type C

Orphazyme announces withdrawal of European Marketing Authorisation Application for arimoclomol for the treatment of Niemann-Pick disease typ...

GlobeNewswire • 22 Mar 2022 11:54

Orphazyme A/S has filed for voluntary delisting of ADSs

Orphazyme A/S has filed for voluntary delisting of ADSs

GlobeNewswire • 21 Mar 2022 22:44

Notice of in-court restructuring proceedings of Orphazyme A/S

Notice of in-court restructuring proceedings of Orphazyme A/S

GlobeNewswire • 18 Mar 2022 11:40

Commencement of in-court restructuring of Orphazyme A/S

Commencement of in-court restructuring of Orphazyme A/S

GlobeNewswire • 10 Mar 2022 22:05

Updated Financial Calender for 2022

Updated Financial Calender for 2022

GlobeNewswire • 03 Mar 2022 09:35

Anders Vadsholt takes over as CEO of Orphazyme

Anders Vadsholt takes over as CEO of Orphazyme

GlobeNewswire • 28 Feb 2022 08:25

Orphazyme announces update on regulatory review of arimoclomol in the European Union

Orphazyme announces update on regulatory review of arimoclomol in the European Union

GlobeNewswire • 23 Feb 2022 22:05

Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering Program

Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.

GlobeNewswire • 18 Feb 2022 22:01

Resolutions passed at the Extraordinary General Meeting

Resolutions passed at the Extraordinary General Meeting

GlobeNewswire • 15 Feb 2022 18:15

Amendment of proposals put forward at the Extraordinary General Meeting

Amendment of proposals put forward at the Extraordinary General Meeting

GlobeNewswire • 14 Feb 2022 22:01

Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type C in the United States

Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type C in the United States

GlobeNewswire • 11 Feb 2022 07:50

Orphazyme to present additional data on arimoclomol’s mechanism of action during 2022 Annual WORLDSymposium™

Orphazyme to present additional data on arimoclomol’s mechanism of action during 2022 Annual WORLDSymposium™

GlobeNewswire • 07 Feb 2022 12:22

Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO

Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO

GlobeNewswire • 31 Jan 2022 17:00

Notice to convene Extraordinary General Meeting

Notice to convene Extraordinary General Meeting

GlobeNewswire • 24 Jan 2022 22:15

Orphazyme updates 2021 financial outlook

Orphazyme updates 2021 financial outlook

GlobeNewswire • 18 Jan 2022 22:15

Orphazyme announces changes to the Board of Directors

Orphazyme announces changes to the Board of Directors

GlobeNewswire • 09 Dec 2021 06:45

Financial Calendar 2022

Financial Calendar 2022

GlobeNewswire • 19 Nov 2021 09:06

Orphazyme establishes a U.S. At-the-Market Offering Program with Cowen

Orphazyme establishes a U.S. At-the-Market Offering Program with Cowen

GlobeNewswire • 04 Nov 2021 13:22

Orphazyme provides regulatory update following Type A meeting with FDA on arimoclomol in Niemann-Pick disease type C

Orphazyme provides regulatory update following Type A meeting with FDA on arimoclomol in Niemann-Pick disease type C

GlobeNewswire • 31 Oct 2021 21:00

Modified long-term share-based incentive program for 2021

Modified long-term share-based incentive program for 2021

GlobeNewswire • 07 Oct 2021 08:40

Orphazyme provides regulatory and financial updates

Orphazyme provides regulatory and financial updates

GlobeNewswire • 05 Oct 2021 08:55

Orphazyme reports business highlights and financial results in Interim Report First Half 2021

Orphazyme reports business highlights and financial results in Interim Report First Half 2021

GlobeNewswire • 31 Aug 2021 07:00

Orphazyme to host Interim Report First Half 2021 investor call on August 31, 2021

Orphazyme to host Interim Report First Half 2021 investor call on August 31, 2021

GlobeNewswire • 25 Aug 2021 14:33

Orphazyme announces publication of results from its Phase 2/3 trial of arimoclomol in Niemann-Pick disease type C in the Journal of Inherited Metabolic Disease

Orphazyme announces publication of results from its Phase 2/3 trial of arimoclomol in Niemann-Pick disease type C in the Journal of Inherite...

GlobeNewswire • 23 Aug 2021 11:04

New publication date for Orphazyme’s Interim Report H1 2021

New publication date for Orphazyme’s Interim Report H1 2021

GlobeNewswire • 05 Aug 2021 18:11

Orphazyme presents 36-month data supporting durable response to arimoclomol during Parseghian Scientific Conference for NPC Research

Orphazyme presents 36-month data supporting durable response to arimoclomol during Parseghian Scientific Conference for NPC Research

GlobeNewswire • 28 Jun 2021 08:00

Orphazyme announces restructuring to focus resources on supporting a path forward for arimoclomol in NPC

Orphazyme announces restructuring to focus resources on supporting a path forward for arimoclomol in NPC

GlobeNewswire • 28 Jun 2021 06:00

Major shareholder announcement

Major shareholder announcement

GlobeNewswire • 24 Jun 2021 13:31

Major shareholder announcement

Major shareholder announcement

GlobeNewswire • 23 Jun 2021 11:43

Orphazyme provides regulatory update from FDA on arimoclomol for Niemann-Pick disease type C

Orphazyme provides regulatory update from FDA on arimoclomol for Niemann-Pick disease type C

GlobeNewswire • 18 Jun 2021 07:00

Major shareholder announcement

Major shareholder announcement

GlobeNewswire • 15 Jun 2021 17:05

Orphazyme addresses recent trading activity

Orphazyme addresses recent trading activity

GlobeNewswire • 11 Jun 2021 09:42

Orphazyme announces topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS)

Orphazyme announces topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS)

GlobeNewswire • 07 May 2021 07:00

Orphazyme to present at upcoming investor conferences

Orphazyme to present at upcoming investor conferences

GlobeNewswire • 27 Apr 2021 22:05

New long-term share-based incentive program

New long-term share-based incentive program

GlobeNewswire • 22 Apr 2021 06:34

Orphazyme announces topline results from pivotal trial of arimoclomol for Inclusion Body Myositis (IBM)

Orphazyme announces topline results from pivotal trial of arimoclomol for Inclusion Body Myositis (IBM)

GlobeNewswire • 29 Mar 2021 07:00

Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities

Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities

GlobeNewswire • 25 Mar 2021 20:48

Articles of Association for Orphazyme A/S

Articles of Association for Orphazyme A/S

GlobeNewswire • 25 Mar 2021 20:37

Capital increase of 3,854 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units

Capital increase of 3,854 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units

GlobeNewswire • 25 Mar 2021 20:20

Resolutions passed at the Annual General Meeting

Resolutions passed at the Annual General Meeting

GlobeNewswire • 25 Mar 2021 18:53

Correction: Notice to convene Annual General Meeting

Correction: Notice to convene Annual General Meeting

GlobeNewswire • 03 Mar 2021 19:06

Notice to convene Annual General Meeting

Notice to convene Annual General Meeting

GlobeNewswire • 03 Mar 2021 16:00

Orphazyme reports business highlights and financial results in Annual Report 2020

Orphazyme reports business highlights and financial results in Annual Report 2020

GlobeNewswire • 02 Mar 2021 07:00

Orphazyme appoints Christophe Bourdon as Chief Executive Officer

Orphazyme appoints Christophe Bourdon as Chief Executive Officer

GlobeNewswire • 01 Mar 2021 07:00

Orphazyme announces participation in upcoming virtual investor conferences

Orphazyme announces participation in upcoming virtual investor conferences

GlobeNewswire • 26 Feb 2021 21:38

Capital increase of 80,553 shares (equivalent to approximately 0.23% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KUMCRI and directed issuance of new shares

Capital increase of 80,553 shares (equivalent to approximately 0.

GlobeNewswire • 25 Feb 2021 22:01

Orphazyme announces presentation of 2020 Annual Report

Orphazyme announces presentation of 2020 Annual Report

GlobeNewswire • 23 Feb 2021 15:10